Please use this identifier to cite or link to this item:
|Title:||Report from the EPAA Workshop: In vitro ADME in Safety Testing used by EPAA industry sectors|
|Authors:||SCHROEDER Klausrudolf; BREMM Klaus-Dieter; ALEPEE Natalie; BESSEMS Jos; BLAAUBOER Bas J; BOEHN Susanne; BUREK Christof; COECKE Sandra; GAMBOU Lourdes; HEWITT Nicky; HEYLINGS Jon; HUWYLER Joerg; JAEGER Martina; JAGELAVICIUS Marius; JARRETT Nicholas; KETELSLEGERS Hans; KOCINA Iveta; KOESTER Johannes; KREYSA JOACHIM; NOTE Raymond; POTH Albrecht; RADTKE Martin; ROGIERS Vera; SCHEEL Julia; SCHULZ Thomas; STEINKELLNER Hans; TOEROEK Michael; WHELAN Maurice; WINKLER Petra; DIEMBECK Walter|
|Citation:||TOXICOLOGY IN VITRO vol. 25 no. 3 p. 589–604|
|Publisher:||PERGAMON-ELSEVIER SCIENCE LTD|
|JRC Publication N°:||JRC61611|
|Type:||Articles in Journals|
|Abstract:||There are now numerous in vitro and in silico ADME alternatives to in vivo assays but how do different industries incorporate them into their decision tree approaches for risk assessment, bearing in mind that the chemicals tested are intended for widely varying purposes? The extent of the use of animal tests is mainly driven by regulations or by the lack of a suitable in vitro model. Therefore, what considerations are needed for alternative models and how can they be improved so that they can be used as part of the risk assessment process? To address these issues, the European Partnership for Alternative Approaches to Animal Testing (EPAA) working group on prioritisation, promotion and implementation of the 3Rs research held a workshop in November, 2008 in Duesseldorf, Germany. Participants included different industry sectors such as pharmaceuticals, cosmetics, industrial- and agro-chemicals. This report describes the outcome of the discussions and recommendations (a) to reduce the number of animals used for determining the ADME properties of chemicals and (b) for considerations and actions regarding in vitro and in silico assays. These included: standardisation and promotion of in vitro assays so that they may become accepted by regulators; increased availability of industry in vivo kinetic data for a central database to increase the power of in silico predictions; expansion of the applicability domains of in vitro and in silico tools (which are not necessarily more applicable or even exclusive to one particular sector) and continued collaborations between regulators, academia and industry. A recommended immediate course of action was to establish an expert panel of users, developers and regulators to define the testing scope of models for different chemical classes. It was agreed by all participants that improvement and harmonization of alternative approaches is needed for all sectors and this will most effectively be achieved by stakeholders from different sectors sharing data.|
|JRC Institute:||Institute for Health and Consumer Protection|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.